{"id":404,"date":"2022-02-15T10:56:31","date_gmt":"2022-02-15T10:56:31","guid":{"rendered":"https:\/\/www.fnfresearch.com\/blog\/?p=404"},"modified":"2022-02-15T10:56:31","modified_gmt":"2022-02-15T10:56:31","slug":"ensovibep-and-sotrovimab-advance-in-their-fight-against-covid-19","status":"publish","type":"post","link":"https:\/\/www.fnfresearch.com\/blog\/ensovibep-and-sotrovimab-advance-in-their-fight-against-covid-19\/404\/","title":{"rendered":"Ensovibep and Sotrovimab advance in their fight against COVID-19"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\r\n<div class=\"ez-toc-title-container\">\r\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\r\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\r\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.fnfresearch.com\/blog\/ensovibep-and-sotrovimab-advance-in-their-fight-against-covid-19\/404\/#Molecular_Partners_AG\" >Molecular Partners AG:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.fnfresearch.com\/blog\/ensovibep-and-sotrovimab-advance-in-their-fight-against-covid-19\/404\/#Vir_Biotechnology\" >Vir Biotechnology:<\/a><\/li><\/ul><\/nav><\/div>\r\n<p>Molecular Partners AG (MOLN), a clinical-stage biotechnology firm, is seeking emergency use authorization from the US FDA for ensovibep, a designed ankyrin repeat <a href=\"https:\/\/www.fnfresearch.com\/blog\/a-toilet-based-device-employs-artificial-intelligence-to-monitor-biomarkers-for-utis\/399\/\">protein<\/a> (DARPin) antiviral therapy candidate to treat COVID-19 through its partner.<\/p>\n<p>MOLN is working on DARPin therapies, a novel class of custom-built protein therapies. Ensovibep is specially developed to prevent <a href=\"https:\/\/www.fnfresearch.com\/blog\/glycans-help-sars-cov-2-virus-evade-human-cells\/1\/\">SARS-CoV-2<\/a>, the virus that causes COVID-19, from entering target cells.<\/p>\n<p>Vir Biotechnology, Inc. (VIR), a commercial-stage immunology company, also made headlines when it announced that preclinical data suggests that sotrovimab, an investigational MAB (monoclonal antibody) approved for emergency use in the US, retains neutralizing activity against the BA.2 subvariant of Omicron.<\/p>\n<p>Sotrovimab is an investigational SARS CoV2 neutralizing monoclonal antibody, according to the Vir team. The antibody binds to SARS CoV2 and SARS CoV1 (the virus that causes SARS), making it more difficult to develop resistance.<\/p>\n<p>According to Vir&#8217;s CEO, George Scangos, the data confirms the ongoing importance of sotrovimab as a vital treatment in the battle against the ever-evolving SARS-CoV-2 virus.<\/p>\n<p>&#8220;We highlight recent findings from another lab stating that no authorized or approved monoclonal antibodies for treatment preserve activity against all Omicron subvariants. &#8220;We are therefore glad to report that, depending on our pseudovirus and detailed pharmacokinetic data, we anticipate the 500-dose range of sotrovimab is adequate to sustain an action against the BA.2 variant, as well as all other variants of interest and concern. &#8221;<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Molecular_Partners_AG\"><\/span><strong>Molecular Partners AG:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Molecular Partners AG is a clinical-stage biotech firm that is developing DARPin therapies, a novel class of custom-built protein medications that are meant to tackle challenges that conventional therapies cannot. The company has created collaborations with top pharmaceutical firms to enhance DARPin therapies in oncology, ophthalmology, and infectious diseases, and has compounds in different stages of preclinical and clinical development across many therapeutic domains.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Vir_Biotechnology\"><\/span><strong>Vir Biotechnology:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Vir Biotechnology is a commercial-stage immunology firm that aims to treat and prevent major infectious diseases by merging immunologic information with cutting-edge techniques.<br \/>\n[embedsocial_schema id=&#8221;d4ae80cffae3d938f997111953699a733c8e6f99&#8243;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Molecular Partners AG (MOLN), a clinical-stage biotechnology firm, is seeking emergency use authorization from the US FDA for ensovibep, a designed ankyrin repeat protein (DARPin) antiviral therapy candidate to treat COVID-19 through its partner. MOLN is working on DARPin therapies,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":10,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[133,132,134],"class_list":["post-404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare","tag-ensovibep","tag-ensovibep-and-sotrovimab","tag-sotrovimab"],"_links":{"self":[{"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/posts\/404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/comments?post=404"}],"version-history":[{"count":0,"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/posts\/404\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/media\/10"}],"wp:attachment":[{"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/media?parent=404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fnfresearch.com\/blog\/wp-json\/wp\/v2\/tags?post=404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}